In­novent and Eli Lil­ly chal­lenge Mer­ck­'s mega-block­buster Keytru­da in non-small cell lung can­cer field

Chi­na-based In­novent Bi­o­log­ics and its multi­na­tion­al al­ly Eli Lil­ly shared Phase III ev­i­dence that their PD-1 in­hibitor com­bo can de­lay the pro­gres­sion of non­squa­mous non-small cell lung can­cer.

But the drug­mak­ers will face stiff com­pe­ti­tion in Chi­na from Mer­ck’s Keytru­da, the rul­ing PD-1 which is al­ready ap­proved to treat both squa­mous and non­squa­mous NSCLC and boasts pos­i­tive over­all sur­vival rates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.